China Biotech News

China Biotech Group, a leading biotechnology company today announced a Joint Venture with China Stem Cell (CSC) which will launch a cancer cell therapy program.

since 2011, because of the obviously declining batch release of biological products YOY influenced by the implementation of new version GMP, the export amount of biochemical drugs keeps a slow growth rate.

Monoclonal antibody still belongs to high-end products in Chinese market, mainly depending on imports.

Co-founder Derek Muhs transitions from role as CEO to Group President and Dr Steve Liu, PhD appointed as new Group CEO.

The 3rd edition of lactic acid & polylactic acid benchmarking report has been published by CCM International in February 2012.

China Biotech Group, a leading biotechnology company today announced a Joint Venture with China Stem Cell (CSC) which will launch a cancer cell therapy program.

since 2011, because of the obviously declining batch release of biological products YOY influenced by the implementation of new version GMP, the export amount of biochemical drugs keeps a slow growth rate.

Monoclonal antibody still belongs to high-end products in Chinese market, mainly depending on imports.

To give you suggestions on MSG industry, CCM International created a new report in February, 2012, entitled Production and Market of Monosodium Glutamate (MSG) in China.

Co-founder Derek Muhs transitions from role as CEO to Group President and Dr Steve Liu, PhD appointed as new Group CEO.

Pangang plans to recapitalize Dongfang Titanium, in order to strengthen TiO2 business.

The output value of China's fermentation industry is expected to reach USD72.6 billion by 2015, according to CCM International’s January issue of Corn Products China News.

Chinese PHA manufacturers are optimistic about the future PHA market since the plastic ban is estimated to be implemented gradually in Europe and in the US.

Many people are traveling to China’s top tier cities, not for business or vacation, but to receive medical treatments unavailable in their home countries, such as stem cell therapies.

CCM International has published the latest report of Cost & Profit Analysis of Key Xanthan Gum Producers in China in December 2011.

Leading-Tech Laser CO.,LTD today announced it has initiated new series of line lasers: 1° mid power line lasers, The latest series of line laser features the high uniformity along the whole laser line with the smallest fan angle of 1°.

WA Regenerative Medicine signed a milestone agreement today with University of Southern California, which aims at sharing research, and applying breakthrough medicine to help improve the lives of people in the Greater China Region.

WA signs contract to implement clinical trials of mesenchymal stem cell treatment of Parkinson’s disease.

WA Stem Cell Technologies signed an agreement to secure space in Shanghai Ju-Ke Biotech Park, designed to support biotechnologies, pharmaceutical research and development and clinical research.

Announcing Professor Dai Jianping as President of the WA Stem Cell Technologies Medical and Technology Board

June event provides unique platform for business leaders and innovators to dialog and learn about the latest trends and future directions of emerging technologies.

Leading-Tech Laser offer fiber coupled dpss lasers and diode collimated lasers with high fiber coupling efficiency, excellent beam quality, long power stability.

Crystal Pharmatech, the first solid state pharmaceutical research CRO in China, announced that Robert Wenslow, Ph.D. has joined its executive committee as Vice President of Business Development, effective April 4th, 2011.

Survey shows that in China, the proportion of children aged 0-4 who suffer from respiratory diseases and digestive system diseases in the age group suffering from them accounts for about 80% and 10% respectively, totaling up to 90%.

The operation mode of China's animal FMD vaccine industry is as follows: the outbreak-> the local government invites public bidding ->the production of enterprises->the distribution of the local government.

After completing the clinical trial on over 30 patients with effectiveness at 100%, Sino Stem Cells, introduces diabetes clinically. 62.9% reduced insulin dosage by 50%. 3.7% of Type 1 and 11.1% of Type 2 could completely stop insulin injections.

Wujing General Hospital announced the launch of the Arabic version of its website, as one of the steps towards improving the quality of its international patient services.

The Ministry of Health of China introduced new regulations governing the clinical use of stem cells. We provide a quick digest of the laws regulating new biotechnologies including stem cell treatments in China which came into force from 1 May 2009.

Leading-Tech Laser have announced new product: the free space semiconductor laser module of 750nm. The LTL750S combines high performance semiconductor lasers.

Crystal Pharmatech focuses on the specialized field of solid state information for active pharmaceutical ingredients and formulations. Its core services include: salt/polymorph screening, cocrystal screening, chiral resolution, and solid state NMR.

The annual World Stem Cell Summit was held in Detroit, USA in October 2010 aimed to promote stem cell research and its clinical application to develop therapies for debilitating conditions like Brain and Spinal Cord Injuries.

Secretary of the Wuxi Municipal Committee of the CPC Attends Launch of WA Bio-tech Facilities in Wuxi, China.

Leading-Tech Laser CO.,LTD could offer single mode polarization maintaining fiber coupled DPSS lasers or didoe collimated lasers with excellent beam quality, low M2 factor, long time power stability and long life time.

At present, statins are the prior choices in Chinese hypolipidemic agent sector. Nevertheless, with the growth in the use of statins, the probability of untoward effects is rising.

From January to November of 2008, the sales revenue of Chinese manufacturing industry on biological products and biochemical products totaled RMB 64.248 billion, increasing by 29.81% YOY.

It is estimated that purchasing and stockpiling price of A (H1N1) influenza vaccines will be quite low. But the net profit rate will not be lower than common influenza vaccines, which is estimated to be about 60%.

Generally, high-price vaccines have a price reduction and low-price vaccines have a rising price. High-price products like Measles Mumps& Rubella Vaccine Live and Measles & Rubella Combined Vaccine (MR) have a price reduction of 35% and 47%.

In 2009, 23.3 million populations will need vaccinating, accounting for 31% of the populations that should be vaccinated.

This report examines the current state of the disease management industry, highlights the challenges and opportunities facing the industry, and discusses technology's role in driving innovations in new care management models.

WWW.SHCRI.COM -- Research Report on China's foot-and-mouth disease Vaccine (FMD Vaccine) Industry, 2009

NEVER SAY DIE! Death is for poor people, RICH can live a great life again, and again... IF...

New health care discovery non-toxic natural chemotherapy TM, to get rid of cancer...

"MIND ACUPUNCTURE TM" NEW HEALTH CARE DISCOVERY, to cure mind body diseases...time is of essence to start as soon as possible to do it...

Fantastic Idea: Use of TCM & Acupuncture Medicine to help to learn a new language...idea has arrived and it is going to help millions of Chinese English Language Learners...

Research Report on China's Biopharmaceutical Industry, 2009

EnoGene’s Italian distributor, the ISO 9001 certified company Prodotti Gianni SpA, since 1950 in the research market, is promoting EnoGene’s high quality antibody products and services in Italy.

Breakthrough technology in microscopy brings advancements that provide customers with the power to discover things they have never seen before, and to solve problems never before solvable.

Infinity I-China announced on that it has joined with Kleiner Perkins Caufield & Byers China, the China Spring Fund and JAIC in a Series B Financing round of Chiral Quest Corporation.

ResearchInChina announces the release of a new report - China Blood Products Industry Report, 2007-2008. For ordering information please contact us at report@researchinchina.com or at 86-10-82600821.

Market Report on China's Biopharmaceutical Industry, 2008-2010

Suzlon Energy, the largest wind turbine manufacturer in Asia and the fifth largest in the world, has just signed a training deal with China-based training firm Yaxley Education.

Research Report on China Blood Product Market, 2008

Liquid fuel synthesis: Making it up as you go along

Americans are going to China for stem cell treatments and having success.